MedTrace Logo

Assessment of the Safety and Efficacy of the Dermal Filler "mARG-01-17" in Facial Rejuvenation Therapy

NCT04643977 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-11-25

No results posted yet for this study

Summary

The aim of the clinical investigation is to evaluate the performance of the mARG-01-17 dermal filler in the context of its efficacy and safety.

Conditions

  • Facial Rejuvenation

Interventions

DEVICE

mARG-01-17 (mesohyal AGRIBENONE)

Dermal Filler

Sponsors & Collaborators

  • Mesoestetic Pharma Group S.L.

    lead INDUSTRY

Principal Investigators

  • Tatyana Bayateva, MD · Medical Center Asklepii" OOD

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-30
Primary Completion
2018-12-18
Completion
2018-12-18

Countries

  • Bulgaria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04643977 on ClinicalTrials.gov